Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
Open Access
- 5 May 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (21), 2204-2206
- https://doi.org/10.1001/jama.2021.7489
Abstract
In contrast to immunocompetent participants in vaccine trials,1,2 a low proportion (17%) of solid organ transplant recipients mounted a positive antibody response to the first dose of SARS-CoV-2 messenger RNA (mRNA) vaccines, with those receiving anti–metabolite maintenance immunosuppression less likely to respond.3 In this study, we assessed antibody response after the second dose.Keywords
This publication has 6 references indexed in Scilit:
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturerClinica Chimica Acta; International Journal of Clinical Chemistry, 2021
- Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing TitersJournal of Clinical Microbiology, 2021
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesThe New England Journal of Medicine, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportThe New England Journal of Medicine, 2020
- Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor populationJCI Insight, 2020